Advertisement
ALXO vs AXON
Which Stock Would AI Choose? ALX Oncology Holdings (ALXO) vs. Axon Enterprise (AXON) Stock Comparison
Key Takeaways
- ALXO is a clinical-stage, pre-revenue immuno-oncology biotech, while AXON is a profitable, fast-growing public-safety technology company — a stark contrast in business maturity and risk profile.
- Axon generates strong recurring revenue, with annual recurring revenue (ARR) up 39% to roughly $1.6 billion, while ALX Oncology reports no product revenue and relies on cash runway and clinical catalysts.
- AXON has been repriced sharply lower in recent months — down more than 50% from its 2025 peak — despite continued revenue growth, while ALXO trades near multi-year lows with a small market capitalization.
- ALXO's valuation hinges on binary clinical-trial outcomes for its lead drug evorpacept, whereas AXON's story centers on execution, margin compression, and valuation reset in a premium-growth stock.
- Analyst consensus is "Strong Buy" for ALXO and "Buy" for AXON, though the two ratings reflect very different underlying risk and reward frameworks.
- Investors can track more details on ALXO Major News and ALXO Today's Price Move, as well as AXON Major News and AXON Today's Price Move, for timely updates on each name.
- For automated, data-driven market analysis, explore Trending AI Robots to see which strategies are currently favored by AI trading systems.
Introduction
Comparing ALXO (ALX Oncology Holdings) and AXON (Axon Enterprise) is, in many ways, a study in opposites. One is a small, clinical-stage biotechnology company with no product revenue whose fortunes depend on drug-trial data; the other is a multi-billion-dollar, revenue-generating leader in public-safety technology and software. This stock comparison is most relevant for investors weighing high-risk, catalyst-driven biotech exposure against a growth company undergoing a valuation reset. Both names have experienced meaningful volatility in recent market activity, making their relative performance and market positioning a useful lens for traders and longer-term investors alike.
ALXO Overview and Recent Performance
ALX Oncology Holdings is a clinical-stage immuno-oncology company focused on therapies for cancer patients. Its lead candidate, evorpacept, is a CD47-blocking therapeutic (a drug that blocks a "don't eat me" signal used by cancer cells to evade the immune system), and it is being studied in combination with other anti-cancer agents across multiple tumor types. A second candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate (ADC), a therapy that delivers a toxic payload directly to cancer cells.
In recent weeks, sentiment around ALXO has been shaped primarily by clinical data. Management presented results showing that evorpacept combined with zanidatamab produced durable responses in heavily pre-treated HER2-positive breast cancer patients, particularly those with high CD47 expression. The company has also received FDA Fast Track designations (a designation that can accelerate drug review) for evorpacept in certain indications. Despite these signals, the stock trades near its 52-week lows with a market capitalization well under $200 million, reflecting both the company's pre-revenue status and the binary risk inherent in clinical-stage biotech. Analyst consensus remains "Strong Buy," but the path to value realization depends heavily on upcoming trial readouts and regulatory progress.
AXON Overview and Recent Performance
Axon Enterprise is a public-safety technology company best known for its TASER conducted electrical weapons and body cameras, alongside a growing software and AI platform that includes evidence management, records tools, and counter-drone (Dedrone) capabilities. The company has evolved from a hardware maker into a recurring-software business, with annual recurring revenue (ARR) up 39% to about $1.6 billion and net revenue retention near 126%.
Recent market activity for AXON has been volatile. The shares have declined more than 50% from their 2025 peak and are down roughly 25% year-to-date, even as the company reported quarterly revenue of approximately $904 million (up about 35% year over year) and raised its full-year outlook. A five-day winning streak in late October, tied partly to the unveiling of the Axon Body 5 camera, trimmed some losses. Weighing on sentiment have been concerns about margin compression, a $1 billion convertible-note offering, and the premium valuation that the stock carried at its highs. Consensus is a "Buy" with an average price target well above the current price.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI trading bots. Tickeron maintains hundreds of AI-powered trading bots that collectively monitor thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and set of covered securities. Rather than listing every bot, the Trending section highlights only those best suited to current market conditions, based on recent performance and statistical signals. Bots vary in approach — from short-term swing strategies to longer-term trend following — and their performance statistics span a wide range depending on market regime. Exploring Trending AI Robots can help traders identify which automated strategies are currently aligning with prevailing conditions.
Head-to-Head Comparison
The contrasts between these two companies are fundamental. ALXO operates in biotechnology with a concentrated, binary risk profile: its near-term value is tied almost entirely to evorpacept's clinical outcomes and the company's cash runway, which funds operations without product revenue. Its sector exposure is to oncology drug development, where catalysts such as trial data and FDA decisions drive sharp, event-based price moves.
AXON, by contrast, has a diversified hardware-plus-software model with proven, growing revenue and a strong balance-sheet trajectory. Its growth drivers include AI adoption in public-safety workflows, international expansion, and newer categories like counter-drone technology. Its risks are more execution- and valuation-related: government budget dependence, margin compression during an investment cycle, and the challenge of sustaining premium growth rates. In terms of momentum, AXON has recently shown short-term stabilization after a prolonged drawdown, while ALXO remains in a lower-volatility but fundamentally speculative trading range. For a stock comparison, the trade-off is essentially between a catalyst-driven, high-upside micro-cap and a de-rated but fundamentally profitable growth company.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor AXON for trend consistency and stability, given its established revenue base, recurring-software model, and emerging short-term momentum after a deep correction. ALXO's profile is more speculative, with value tied to binary clinical catalysts that AI models typically assess as higher-uncertainty. That said, ALXO's recent positive biomarker data and "Strong Buy" analyst consensus suggest meaningful upside potential if clinical milestones are met. The probabilistic view, therefore, leans toward AXON for relative stability and demonstrated fundamentals, while acknowledging ALXO as a higher-risk, higher-reward candidate whose outcome depends on trial results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALXO is a Hold and AXON is a StrongBuy.
ALXO's RSI Indicator ascends from oversold territory
The RSI Oscillator for ALXO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 38 of the 44 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ALXO just turned positive on October 19, 2026. Looking at past instances where ALXO's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Following a +11.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALXO advanced for three days, in 212 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 46 cases where ALXO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALXO as a result. In 76 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALXO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALXO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. ALXO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.173) is normal, around the industry mean (3.498). P/E Ratio (-1.004) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AXON in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 06, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 52 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 31 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
ALXO | AXON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 82 | |
SMR RATING 1..100 | 98 | 81 | |
PRICE GROWTH RATING 1..100 | 79 | 65 | |
P/E GROWTH RATING 1..100 | 12 | 80 | |
SEASONALITY SCORE 1..100 | n/a | 43 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AXON's Valuation (90) in the Biotechnology industry is in the same range as ALXO (92) in the null industry. This means that AXON’s stock grew similarly to ALXO’s over the last 12 months.
AXON's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as ALXO (100) in the null industry. This means that AXON’s stock grew similarly to ALXO’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as ALXO (98) in the null industry. This means that AXON’s stock grew similarly to ALXO’s over the last 12 months.
AXON's Price Growth Rating (65) in the Biotechnology industry is in the same range as ALXO (79) in the null industry. This means that AXON’s stock grew similarly to ALXO’s over the last 12 months.
ALXO's P/E Growth Rating (12) in the null industry is significantly better than the same rating for AXON (80) in the Biotechnology industry. This means that ALXO’s stock grew significantly faster than AXON’s over the last 12 months.
| ALXO | AXON | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 82% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 69% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 69% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 71% |
| Advances ODDS (%) | 3 days ago 86% | 16 days ago 74% |
| Declines ODDS (%) | 16 days ago 90% | 2 days ago 70% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALXO’s FA Score shows that 1 FA rating(s) are green while AXON’s FA Score has 0 green FA rating(s).
- ALXO’s FA Score: 1 green, 4 red.
- AXON’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALXO’s TA Score shows that 4 TA indicator(s) are bullish while AXON’s TA Score has 4 bullish TA indicator(s).
- ALXO’s TA Score: 4 bullish, 4 bearish.
- AXON’s TA Score: 4 bullish, 5 bearish.
Price Growth
ALXO (@Biotechnology) experienced а -13.95% price change this week, while AXON (@Aerospace & Defense) price change was -25.64% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +5.08%. For the same industry, the average monthly price growth was -0.97%, and the average quarterly price growth was -12.77%.
Reported Earning Dates
ALXO is expected to report earnings on Nov 13, 2026.
AXON is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Aerospace & Defense (+5.08% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
Advertisement
ALXO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALXO has been loosely correlated with MDGL. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ALXO jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To ALXO | 1D Price Change % | ||
|---|---|---|---|---|
| ALXO | 100% | +0.90% | ||
| MDGL - ALXO | 56% Loosely correlated | +0.10% | ||
| AXON - ALXO | 45% Loosely correlated | +4.26% | ||
| AMRN - ALXO | 43% Loosely correlated | -0.34% | ||
| ARVN - ALXO | 38% Loosely correlated | -0.14% | ||
| FHTX - ALXO | 37% Loosely correlated | +10.00% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PSTP | 37.43 | 0.26 | +0.69% |
| Innovator Power Buffer Step-Up Strategy ETF (PSTP) | |||
| FLGR | 33.52 | 0.11 | +0.32% |
| Franklin FTSE Germany ETF (FLGR) | |||
| CGSD | 25.36 | -0.03 | -0.12% |
| Capital Group Short Duration Income ETF (CGSD) | |||
| WIP | 37.43 | -0.10 | -0.27% |
| State Street SPDR FTSE International Government Inflation-Protected Bond ETF (WIP) | |||
| REW | 12.50 | -0.87 | -6.51% |
| ProShares UltraShort Technology (REW) | |||